

Performance in Initiating Clinical Research – Q1 2017-18

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Date of First Patient Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Date Site Ready To Start	Comments	Reasons for delay correspond to:
This report is blank											

Performance in Delivering Clinical Research – Q1 2017-18

REC Number	IRAS Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed	Maximum Number Of Patients Agreed	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Reason For Closure Of Trial
15/EM/0344	183906	A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of Amatuximab in Combination with Pemetrexed and Cisplatin in Subjects with Unresectable Malignant Pleural Mesothelioma (MORab)	Number Agreed	2	2	Date Agreed	31/10/2017	1	11/01/2017	Withdrawn By Sponsor